Skip to main content

Table 14 Surface Under the Cumulative Ranking Curve (SUCRA)

From: Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis

  Lurasidone Cariprazine Olanzapine Quetiapine Aripiprazole Ziprasidone Placebo
Outcome SUCRA (Rank) SUCRA (Rank) SUCRA (Rank) SUCRA (Rank) SUCRA (Rank) SUCRA (Rank) SUCRA (Rank)
Efficacy Outcomes
 MADRS 0.82 (2) 0.49 (4) 0.81 (2) 0.86 (2) 0.28 (6) 0.27 (5) 0.04 (7)
 CGI-BP-S overall 0.85 (1) 0.45 (4) 0.63 (3) 0.75 (2) N/A 0.19 (5) 0.10 (6)
 CGI-BP-S depression 0.95 (1) N/A 0.58 (2) N/A 0.41 (3) N/A 0.06 (4)
 Response 0.96 (1) 0.54 (4) 0.6 (3) 0.86 (2) 0.23 (5) 0.2 (6) 0.1 (6)
 Remission (MADRS ≤12) 0.87 (1) N/A 0.50 (3) 0.84 (2) N/A 0.14 (4) 0.11 (5)
 Remission (MADRS ≤10) 0.88 (1) 0.60 (2) N/A N/A N/A N/A 0.00 (3)
Discontinuation Outcomes
 All-Cause 0.51 (4) 0.53 (4) 0.96 (1) 0.62 (3) 0.07 (7) 0.21 (6) 0.6 (3)
 Due to Efficacy 0.45 (4) 0.61 (3) 0.70 (3) 0.94 (1) 0.50 (4) 0.07 (7) 0.19 (6)
 Due to Adverse Events 0.77 (2) 0.52 (4) 0.56 (4) 0.13 (6) 0.18 (6) 0.5 (4) 0.84 (2)
Metabolic Outcomes
 Change in Body Weight 0.66 (3) 0.45 (4) 0.0 (6) 0.20 (5) 0.75 (2) N/A 0.91 (1)
 ≥ 7% Weight Gain 0.37 (5) 0.47 (4) 0.01 (6) 0.42 (4) 0.77 (2) N/A 0.94 (1)
 Change in glucose 0.78 (1) 0.53 (3) 0.61 (2) 0.20 (5) 0.31 (5) N/A 0.54 (3)
 Change in Triglycerides 0.76 (1) 0.49 (4) 0.40 (4) 0.09 (6) 0.53 (3) N/A 0.70 (2)
 Change in Cholesterol 0.44 (4) 0.84 (1) 0.04 (6) 0.54 (3) 0.54 (3) N/A 0.58 (3)
 Change in LDL 0.30 (6) 0.70 (2) 0.29 (5) 0.60 (2) 0.59 (2) N/A 0.49 (4)
Other Outcomes
 Prolactin 0.01 (5) 0.30 (4) N/A 0.58 (3) 0.73 (2) N/A 0.85 (1)
 Somnolence 0.76 (2) 0.64 (3) 0.38 (5) 0.09 (7) 0.59 (3) 0.11 (6) 0.94 (1)
 EPS 0.22 (5) 0.45 (3) N/A 0.28 (4) 0.57 (2) N/A 0.99 (1)
 Akathisia 0.13 (4) 0.38 (3) N/A N/A 0.51 (2) N/A 0.97 (1)
 Switch to Mania 0.74 (5) 0.41 (3) 0.29 (2) 0.13 (1) 0.88 (6) NA 0.55 (4)